MedTrace Logo

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

NCT03304522 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2021-11-15

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy.

Conditions

  • Small Fiber Neuropathy

Interventions

DRUG

VX-150

Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.

DRUG

Placebo

Participants received placebo matched to VX-150 for 6 weeks.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2018-10-12
Completion
2018-11-08
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03304522 on ClinicalTrials.gov